HIGH GRADE OVARIAN SEROUS ADENOCARCINOMA
Clinical trials for HIGH GRADE OVARIAN SEROUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HIGH GRADE OVARIAN SEROUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for HIGH GRADE OVARIAN SEROUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy targets Hard-to-Treat recurrent cancers
Disease control OngoingThis early-phase trial tests two different drug combinations—olaparib plus vistusertib, or olaparib plus capivasertib—in people with recurrent endometrial, triple-negative breast, ovarian, primary peritoneal, or fallopian tube cancer. The main goal is to find the safest dose and …
Matched conditions: HIGH GRADE OVARIAN SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug shows promise in shrinking ovarian tumors before surgery
Disease control OngoingThis early trial is testing whether the drug olaparib can shrink tumors in people with newly diagnosed BRCA-mutant ovarian, fallopian tube, or peritoneal cancer before they have surgery. Fifteen participants will receive olaparib for two cycles, then undergo standard chemotherapy…
Matched conditions: HIGH GRADE OVARIAN SEROUS ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC